Oral glutamine supplementation increases seizure severity in a rodent model of mesial temporal lobe epilepsy
GLP-1 face refers to the facial volume loss, skin laxity, and accelerated signs of aging observed in patients using GLP-1 receptor agonists for weight loss or diabetes management
Retatrutide has higher nausea, vomiting, and diarrhea rates across all dose levels
Proper timing, dosing protocols, and understanding the synergies between these compounds can significantly enhance body recomposition outcomes
Half-life and steady state Retatrutide's half-life is about 6 days (around 144 hours)
Observational studies and some ophthalmology commentaries have been more reassuring overall, suggesting that many patients taking semaglutide do not experience clinically meaningful retinal worsening